MCID: PLS006
MIFTS: 55

Plasmodium Vivax Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Vivax Malaria

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 12 15
Malaria, Vivax 44 73
Malaria by Plasmodium Vivax 12
Vivax Malaria 12
Malaria Vivax 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12978
ICD9CM 35 084.1
MeSH 44 D016780
NCIt 50 C34800
SNOMED-CT 68 27052006
UMLS 73 C0024537

Summaries for Plasmodium Vivax Malaria

Disease Ontology : 12 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary : Plasmodium Vivax Malaria, also known as malaria, vivax, is related to hemophagocytic lymphohistiocytosis and bronchiolitis obliterans. An important gene associated with Plasmodium Vivax Malaria is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs chloroquine and Artesunate have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and b cells, and related phenotypes are cardiovascular system and cellular

Related Diseases for Plasmodium Vivax Malaria

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 30.5 IFNG IL10 TNF
2 bronchiolitis obliterans 30.0 IFNG IL10 IL6 TNF
3 pulmonary edema 29.7 ICAM1 IL10 TNF
4 pneumonia 29.7 CD40LG IL10 IL6 TNF
5 myocarditis 29.2 CD40LG ICAM1 IL6 TNF
6 bronchiolitis 29.1 CD40LG IFNG IL10 IL6 TNF
7 plasmodium falciparum malaria 27.8 G6PD ICAM1 IFNG IL10 SELE TNF
8 malaria 27.1 ACKR1 ANGPT2 CD40LG G6PD ICAM1 IFNG
9 scorpion envenomation 10.8 IL6 TNF
10 staphylococcal toxic shock syndrome 10.8 IFNG TNF
11 autoimmune myocarditis 10.8 IFNG TNF
12 leukomalacia 10.8 IL6 TNF
13 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL6 TNF
14 punctate inner choroidopathy 10.7 IL10 TNF
15 trichosporonosis 10.7 IFNG TNF
16 chronic beryllium disease 10.7 IFNG TNF
17 streptococcal toxic-shock syndrome 10.7 IL6 TNF
18 tropical endomyocardial fibrosis 10.7 IL10 TNF
19 null-cell leukemia 10.7 IL6 TNF
20 b-cell growth factor 10.7 IFNG IL6
21 retinitis pigmentosa 55 10.7 IL6 TNF
22 microscopic polyangiitis 10.7 IL10 TNF
23 anca-associated vasculitis 10.7 IL6 TNF
24 multifocal choroiditis 10.7 IL10 TNF
25 tungiasis 10.7 IL10 TNF
26 thrombocytopenia 10.7
27 endomyocardial fibrosis 10.7 IL10 TNF
28 laryngitis 10.7 IL6 TNF
29 hyperlucent lung 10.7 IFNG IL10
30 transient hypogammaglobulinemia 10.6 IL10 TNF
31 eye lymphoma 10.6 IL10 IL6
32 acute vascular insufficiency of intestine 10.6 IL6 TNF
33 posterior urethral valves 10.6 IL6 TNF
34 choroiditis 10.6 IL10 TNF
35 crohn's colitis 10.6 IFNG TNF
36 acute transverse myelitis 10.6 IL10 IL6
37 idiopathic achalasia 10.6 IL10 TNF
38 baylisascariasis 10.6 IFNG IL10
39 trichuriasis 10.6 IL10 TNF
40 mucocutaneous leishmaniasis 10.6 IL10 TNF
41 chronic graft versus host disease 10.5 IFNG IL10
42 trench fever 10.5 CD40LG TNF
43 encephalitozoonosis 10.5 CD40LG TNF
44 pericardial tuberculosis 10.5 IFNG IL10
45 rheumatoid lung disease 10.5 CD40LG TNF
46 burning mouth syndrome 10.5 IL6 TNF
47 miller fisher syndrome 10.5 CD40LG TNF
48 relapsing polychondritis 10.5 IFNG IL6
49 tuberculoid leprosy 10.5 IFNG IL10
50 cat-scratch disease 10.5 CD40LG IFNG

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria

Symptoms & Phenotypes for Plasmodium Vivax Malaria

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 IL10 G6PD ICAM1 IL6 ANGPT2 IFNG
2 cellular MP:0005384 10.13 CD40LG IL10 G6PD ICAM1 ANGPT2 IFNG
3 homeostasis/metabolism MP:0005376 10.1 CD40LG IL10 G6PD ICAM1 ACKR1 ANGPT2
4 hematopoietic system MP:0005397 10.03 CD40LG G6PD IL10 ICAM1 IFNG SELE
5 immune system MP:0005387 10.02 CD40LG IL10 ICAM1 ACKR1 ANGPT2 IFNG
6 digestive/alimentary MP:0005381 9.93 IL10 ICAM1 ANGPT2 IFNG TNF IL6
7 integument MP:0010771 9.92 IL10 ICAM1 ANGPT2 IFNG CD40LG TNF
8 mortality/aging MP:0010768 9.91 IFNG CD40LG G6PD IL10 ICAM1 ANGPT2
9 neoplasm MP:0002006 9.55 IFNG IL10 ICAM1 TNF IL6
10 respiratory system MP:0005388 9.43 IL10 ANGPT2 IFNG SELE TNF IL6
11 vision/eye MP:0005391 9.17 IL10 ICAM1 ANGPT2 IFNG SELE TNF

Drugs & Therapeutics for Plasmodium Vivax Malaria

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-05-7 2719
2
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88495-63-0 6917864 5464098
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 22916-47-8 4189
4
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
5
Dihydroartemisinin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
6
Piperaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4085-31-8 5079497
7
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
8
Artemether Approved Phase 4,Phase 3,Phase 1,Not Applicable 71963-77-4 119380 68911
9
Mefloquine Approved, Investigational Phase 4,Phase 3 53230-10-7 4046
10
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
11
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
12
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
14
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
15 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-63-5
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antifungal Agents Phase 4,Phase 3,Phase 1
22 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 1,Not Applicable
28 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
33 Vitamin B Complex Phase 4,Phase 3,Phase 2,Not Applicable
34 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
35 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
36
Proguanil Approved Phase 3 500-92-5 4923
37
Amodiaquine Approved, Investigational Phase 3,Not Applicable 86-42-0 2165
38
Dapsone Approved, Investigational Phase 3 80-08-0 2955
39 Orange Approved, Nutraceutical Phase 3
40
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
41 Tafenoquine Investigational Phase 3,Phase 2,Phase 1 106635-80-7
42
Chlorproguanil Investigational Phase 3 537-21-3 151170 9571037
43
Pyronaridine Investigational Phase 3,Phase 1 74847-35-1 5485198
44 Anti-Bacterial Agents Phase 3
45 Fanasil, pyrimethamine drug combination Phase 3,Phase 2,Not Applicable
46 Antimetabolites Phase 3
47
Methylene blue Approved, Investigational Phase 2 61-73-4
48 Vaccines Phase 1, Phase 2,Not Applicable
49
Ritonavir Approved, Investigational Phase 1 155213-67-5 392622
50
Metoprolol Approved, Investigational Phase 1 37350-58-6, 51384-51-1 4171

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
3 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
4 Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
5 Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
6 A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
7 Effectiveness of Malaria Treatment in Mexico Completed NCT02394197 Phase 4 Chloroquine phosphate;primaquine
8 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
9 A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI) Recruiting NCT02787070 Phase 4 PQ supervised;PQ unsupervised
10 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Not yet recruiting NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
11 Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
12 Prevention of P. Vivax Malaria During Pregnancy in Bolivia Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
13 A Trial on Supervised Primaquine Use in Ethiopia Withdrawn NCT02793388 Phase 4 Supervised primaquine treatment;Unsupervised primaquine treatment
14 Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day Unknown status NCT02020330 Phase 3 Artemether-lumefantrine 3 days;Artemether-lumefantrine 5 days
15 Study on the Treatment of Vivax Malaria Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
16 Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
17 Artemether/Lumefantrine and Vivax Malaria Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
18 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
19 Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
20 Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
21 Eight Week Primaquine Regimen for the Treatment of Vivax Malaria Completed NCT00158587 Phase 3 primaquine
22 Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
23 A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
24 Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria Completed NCT01378286 Phase 3 ARTESUNATE + AMODIAQUINE;Chloroquine
25 P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
26 ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Completed NCT00158548 Phase 3 SP, chloroquine, amodiaquine, primaquine, artesunate
27 Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon Completed NCT01845701 Phase 3 Artesunate-Amodiaquine;Dihydroartemisinine-Piperaquine;Artemether-lumefantrine combination
28 Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia Recruiting NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
29 Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria Recruiting NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
30 DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Not yet recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
31 Methylene Blue Against Vivax Malaria in Ethiopia Unknown status NCT02696928 Phase 2 Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy)
32 Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
33 DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
34 Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
35 Study of VMP001 and AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
36 Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
37 Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
38 Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
39 A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria Recruiting NCT02563496 Phase 2 Tafenoquine;Chloroquine
40 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients Not yet recruiting NCT03529396 Phase 2 Chloroquine;Primaquine;Primaquine;Chloroquine;Primaquine
41 MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria Suspended NCT02880241 Phase 2 MMV390048
42 Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Terminated NCT02110784 Phase 2 Eurartesim tablets
43 Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults Terminated NCT01290601 Phase 2 Tafenoquine;Chloroquine + Primaquine;tafenoquine;Chloroquine + Primaquine
44 A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection Terminated NCT02573857 Phase 1, Phase 2 DSM265;OZ439
45 PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Completed NCT00295581 Phase 1 PpPfs25/ISA51 & ScPvs25/ISA51
46 G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine) Completed NCT01205178 Phase 1 Chloroquine;Primaquine;Tafenoquine
47 Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans Completed NCT00935623 Phase 1
48 Primaquine Pharmacokinetics in Lactating Women and Their Infants Completed NCT01780753 Phase 1 Primaquine
49 Phase Ia Study of ChAd63/MVA PvDBP Completed NCT01816113 Phase 1
50 Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects Completed NCT01218932 Phase 1 A;B

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malaria, vivax

Genetic Tests for Plasmodium Vivax Malaria

Anatomical Context for Plasmodium Vivax Malaria

MalaCards organs/tissues related to Plasmodium Vivax Malaria:

41
Testes, T Cells, B Cells, Neutrophil, Liver, Lung, Kidney

Publications for Plasmodium Vivax Malaria

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 538)
# Title Authors Year
1
Therapeutic and Transmission-Blocking a8"Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia. ( 29798745 )
2018
2
Polymorphisms in TLRs influence circulating cytokines production in Plasmodium vivax malaria: TLR polymorphisms influence cytokine productions in malaria-vivax. ( 29656958 )
2018
3
Biological concepts in recurrent Plasmodium vivax malaria. ( 29564998 )
2018
4
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( 29390987 )
2018
5
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( 29889239 )
2018
6
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( 29361939 )
2018
7
Genetic Spatiotemporal Anatomy of Plasmodium vivax Malaria Episodes in Greece, 2009-2013. ( 29460743 )
2018
8
High risk of Plasmodium vivax malaria following splenectomy in Papua, Indonesia. ( 29771281 )
2018
9
CLINICAL AND IMMUNOLOGICAL PROFILES OF ANAEMIA IN CHILDREN AND ADOLESCENTS WITH PLASMODIUM VIVAX MALARIA IN THE PARA8 STATE, BRAZILIAN AMAZON. ( 29408596 )
2018
10
Distinct inflammatory profile underlies pathological increases in creatinine levels associated with Plasmodium vivax malaria clinical severity. ( 29596409 )
2018
11
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. ( 29357870 )
2018
12
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. ( 29909069 )
2018
13
Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis. ( 28722625 )
2017
14
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( 28850568 )
2017
15
Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria. ( 28813452 )
2017
16
A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. ( 29121061 )
2017
17
Symmetrical Peripheral Gangrene in Severe Plasmodium vivax Malaria. ( 28515614 )
2017
18
Frequent Spread of Plasmodium vivax Malaria Maintains High Genetic Diversity at the Myanmar-China Border without Distance and Landscape Barriers. ( 28329141 )
2017
19
TOLLIP gene variant is associated with Plasmodium vivax malaria in the Brazilian Amazon. ( 28288644 )
2017
20
Autoimmune Hemolytic Anemia in Plasmodium vivax Malaria. ( 28290054 )
2017
21
Metabolome-wide association study of peripheral parasitemia in Plasmodium vivax malaria. ( 28927849 )
2017
22
Parkinsonism and Tremor in a Patient with Plasmodium vivax Malaria. ( 28616358 )
2017
23
A case of Plasmodium vivax malaria presenting as acute cerebral infarct. ( 28748845 )
2017
24
An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. ( 28695821 )
2017
25
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria. ( 28975866 )
2017
26
Genomic variation in Plasmodium vivax malaria reveals regions under selective pressure. ( 28493919 )
2017
27
Household level spatio-temporal analysis of Plasmodium falciparum and Plasmodium vivax malaria in Ethiopia. ( 28427451 )
2017
28
Malaria cases in Switzerland from 2005 to 2015 and recent rise of imported Plasmodium vivax malaria. ( 29063526 )
2017
29
What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates? ( 28243235 )
2017
30
No Ordinary Sleeper Cell: Managing the Varied Problems of Plasmodium vivax Malaria. ( 28910476 )
2017
31
Are respiratory complications of Plasmodium vivax malaria an underestimated problem? ( 29273053 )
2017
32
Neurological involvement associated with Plasmodium vivax malaria from Pakistan. ( 28792284 )
2017
33
Underdiagnosed Complicated Plasmodium vivax Malaria in a Child: Need to Think. ( 28761494 )
2017
34
Association of TLR variants with susceptibility to Plasmodium vivax malaria and parasitemia in the Amazon region of Brazil. ( 28850598 )
2017
35
IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children. ( 28946883 )
2017
36
Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia. ( 28300558 )
2017
37
Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. ( 27107287 )
2016
38
Epidemiology of Plasmodium vivax Malaria in India. ( 27708188 )
2016
39
Severe acute respiratory distress syndrome secondary to Plasmodium vivax malaria. ( 26968294 )
2016
40
Micronutrient Deficiencies and Plasmodium vivax Malaria among Children in the Brazilian Amazon. ( 26963624 )
2016
41
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. ( 26919472 )
2016
42
Epidemiology of Plasmodium vivax Malaria in Peru. ( 27799639 )
2016
43
Fatal Primaquine-Induced Hemolysis in a Patient With Plasmodium vivax Malaria and G6PD A(-) Variant in the Brazilian Amazon. ( 26826373 )
2016
44
Primaquine treatment and relapse in Plasmodium vivax malaria. ( 27077309 )
2016
45
Evaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria. ( 27430284 )
2016
46
Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria. ( 27030414 )
2016
47
Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ( 26818020 )
2016
48
Nitric Oxide-Dependent Endothelial Dysfunction and Reduced Arginine Bioavailability in Plasmodium vivax Malaria but No Greater Increase in Intravascular Hemolysis in Severe Disease. ( 27630198 )
2016
49
Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. ( 27528800 )
2016
50
Sharp increase of imported Plasmodium vivax malaria seen in migrants from Eritrea in Hamburg, Germany. ( 27316351 )
2016

Variations for Plasmodium Vivax Malaria

Expression for Plasmodium Vivax Malaria

Search GEO for disease gene expression data for Plasmodium Vivax Malaria.

Pathways for Plasmodium Vivax Malaria

Pathways related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 CD40LG ICAM1 IFNG IL10 IL6 TNF
2
Show member pathways
12.73 CD40LG ICAM1 IFNG IL10 IL6 TNF
3
Show member pathways
12.72 DDX39B ICAM1 IFNG IL6 TNF
4
Show member pathways
12.56 IFNG IL10 IL6 TNF
5
Show member pathways
12.5 ANGPT2 ICAM1 IL6 TNF
6
Show member pathways
12.5 ANGPT2 IFNG IL10 IL6 TNF
7 12.49 CD40LG IFNG IL10 TNF
8
Show member pathways
12.37 IFNG IL10 IL6 TNF
9
Show member pathways
12.28 ICAM1 IFNG IL6 TNF
10
Show member pathways
12.24 CD40LG IFNG IL10 IL6 TNF
11
Show member pathways
12.2 IFNG IL10 IL6 TNF
12
Show member pathways
12.19 CD40LG IFNG IL10 TNF
13
Show member pathways
12.18 IFNG IL6 TNF
14 12.16 IFNG IL10 IL6 TNF
15
Show member pathways
12.12 IL10 IL6 TNF
16
Show member pathways
12.1 IFNG IL6 TNF
17 12.09 IFNG IL6 TNF
18 12.09 IL10 IL6 TNF
19 12.02 CD40LG ICAM1 SELE
20 12.02 ICAM1 IFNG SELE TNF
21
Show member pathways
12 ANGPT2 ICAM1 IFNG IL10 IL6
22 11.94 ICAM1 IFNG IL6 TNF
23 11.91 IFNG IL10 IL6 TNF
24 11.89 ICAM1 IL10 IL6 TNF
25 11.86 ANGPT2 IFNG IL6
26 11.86 ICAM1 IL6 SELE TNF
27 11.83 CD40LG ICAM1 TNF
28 11.81 IFNG IL10 IL6
29 11.79 ICAM1 IL6 SELE TNF
30 11.76 IFNG IL10 IL6 TNF
31 11.74 IFNG IL10 TNF
32
Show member pathways
11.72 CD40LG IFNG TNF
33 11.71 IL10 IL6 TNF
34 11.71 ICAM1 IFNG IL6 TNF
35 11.62 ICAM1 IFNG IL6 SELE
36 11.56 IFNG IL6 SELE
37 11.54 IFNG IL10 IL6 TNF
38 11.52 IFNG IL6 TNF
39 11.49 ICAM1 IL6 TNF
40 11.44 IFNG IL6 TNF
41
Show member pathways
11.43 CD40LG ICAM1 IFNG IL6 SELE TNF
42 11.32 IL10 IL6 TNF
43 11.31 ICAM1 IL10 IL6 TNF
44 11.27 IFNG IL6 TNF
45 11.13 IFNG IL10
46 11.11 ICAM1 IFNG
47 11.04 IL6 TNF
48 11.03 IFNG IL10 IL6 TNF
49 10.98 ICAM1 IFNG IL10 IL6 SELE TNF
50 10.97 IL6 TNF

GO Terms for Plasmodium Vivax Malaria

Cellular components related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 ANGPT2 CD40LG ICAM1 IFNG IL10 IL6

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.89 ICAM1 IL10 IL6 TNF
2 immune response GO:0006955 9.89 CD40LG IFNG IL10 IL6 TNF
3 regulation of signaling receptor activity GO:0010469 9.88 CD40LG IFNG IL10 IL6 TNF
4 leukocyte migration GO:0050900 9.81 ANGPT2 ICAM1 SELE TNF
5 response to organic cyclic compound GO:0014070 9.79 ANGPT2 G6PD ICAM1
6 positive regulation of DNA binding transcription factor activity GO:0051091 9.78 IL10 IL6 TNF
7 response to glucocorticoid GO:0051384 9.72 IL10 IL6 TNF
8 humoral immune response GO:0006959 9.7 IFNG IL6 TNF
9 protein import into nucleus, translocation GO:0000060 9.65 IFNG TNF
10 negative regulation of interleukin-6 production GO:0032715 9.65 IL10 TNF
11 positive regulation of interleukin-12 production GO:0032735 9.65 CD40LG IFNG
12 positive regulation of protein complex assembly GO:0031334 9.64 IFNG TNF
13 positive regulation of osteoclast differentiation GO:0045672 9.64 IFNG TNF
14 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
15 leukocyte tethering or rolling GO:0050901 9.63 SELE TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
17 negative regulation of growth of symbiont in host GO:0044130 9.61 IL10 TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL10 TNF
19 negative regulation of lipid storage GO:0010888 9.58 IL6 TNF
20 endothelial cell apoptotic process GO:0072577 9.58 IL10 TNF
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 ICAM1 IFNG TNF
22 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 IL10 TNF
23 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.56 ICAM1 TNF
24 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.56 CD40LG ICAM1 IL6 TNF
25 regulation of immunoglobulin secretion GO:0051023 9.54 CD40LG TNF
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.54 DDX39B IL10 TNF
27 receptor biosynthetic process GO:0032800 9.46 IL10 TNF
28 cellular response to lipopolysaccharide GO:0071222 9.46 ICAM1 IL10 IL6 TNF
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IFNG TNF
30 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
31 leukocyte cell-cell adhesion GO:0007159 9.13 CD40LG ICAM1 SELE
32 inflammatory response GO:0006954 9.1 ACKR1 CD40LG IL10 IL6 SELE TNF

Molecular functions related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CD40LG IFNG IL10 IL6 TNF

Sources for Plasmodium Vivax Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....